Critical Analysis: DarioHealth (NASDAQ:DRIO) vs. Surgical Science Sweden AB (publ) (OTCMKTS:SUSRF)

Surgical Science Sweden AB (publ) (OTCMKTS:SUSRF) and DarioHealth (NASDAQ:DRIO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Surgical Science Sweden AB (publ) and DarioHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surgical Science Sweden AB (publ)	N/A	N/A	N/A
DarioHealth	-169.87%	-54.81%	-33.36%

Analyst Recommendations

This is a summary of recent ratings and price targets for Surgical Science Sweden AB (publ) and DarioHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgical Science Sweden AB (publ)	0	1	0	0	2.00
DarioHealth	1	1	2	0	2.25

DarioHealth has a consensus target price of $10.00, suggesting a potential upside of 35.32%. Given DarioHealth’s stronger consensus rating and higher probable upside, analysts clearly believe DarioHealth is more favorable than Surgical Science Sweden AB (publ).

Valuation & Earnings

This table compares Surgical Science Sweden AB (publ) and DarioHealth”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgical Science Sweden AB (publ)	N/A	N/A	N/A	N/A	N/A
DarioHealth	$22.36 million	3.24	-$41.71 million	($6.13)	-1.21

Surgical Science Sweden AB (publ) has higher earnings, but lower revenue than DarioHealth.

Institutional & Insider Ownership

33.4% of DarioHealth shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DarioHealth beats Surgical Science Sweden AB (publ) on 6 of the 9 factors compared between the two stocks.

About Surgical Science Sweden AB (publ)

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a powerful training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was incorporated in 1997 and is headquartered in Gothenburg, Sweden.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.